Entrada Therapeutics

Entrada Therapeutics is a clinical-stage biopharmaceutical company focusing on transforming patient care by developing a new class of medicines targeting previously inaccessible intracellular mechanisms. Its innovative portfolio of genetic therapies aims to address neuromuscular and inherited retinal diseases, with notable programs targeting Duchenne muscular dystrophy and a partnership with Vertex Pharmaceuticals for myotonic dystrophy type 1.